Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 4:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 30,673 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Study arm Clear all
Active, not recruiting Phase 2 Interventional

Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

NCT05308446
View directory record Official record
Conditions
Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma
Interventions
Cetuximab, Encorafenib, Nivolumab
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
282
States / cities
Goodyear, Arizona • Carmichael, California • Dublin, California + 223 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 4, 2026, 4:00 AM EDT
Recruiting Phase 2 Interventional

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

NCT07504588
View directory record Official record
Conditions
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma, Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Ovarian High Grade Serous Adenocarcinoma, Recurrent Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Primary Peritoneal High Grade Serous Adenocarcinoma
Interventions
Anti-VEGF Monoclonal Antibody, Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Echocardiography Test, Gemcitabine, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pegylated Liposomal Doxorubicin Hydrochloride, Sacituzumab Govitecan
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
7
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 4, 2026, 4:00 AM EDT
Not listed Phase 1 Interventional

Dilated cardiomYopathy iNtervention With Allogeneic MyocardIally-regenerative Cells (DYNAMIC)

NCT02293603
View directory record Official record
Conditions
Dilated Cardiomyopathy (DCM), Ischemic Cardiomyopathy, Nonischemic Cardiomyopathy, Heart Failure
Interventions
Allogeneic Cardiosphere-Derived Cells (CDCs)
Biological
Lead sponsor
Capricor Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Oct 4, 2026, 4:00 AM EDT
Completed Phase 2 Interventional

OGX-427 in Castration Resistant Prostate Cancer Patients

NCT01120470
View directory record Official record
Conditions
Castration Resistant Prostate Cancer
Interventions
OGX-427, Prednisone
Drug
Lead sponsor
British Columbia Cancer Agency
Other
Eligibility
18 Years and older · Male only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 4, 2026, 4:00 AM EDT
Not listed Phase 1Phase 2 Interventional

Measurement of Eye Blood Flow and Renal Function in Healthy and Diabetic Patients

NCT01626469
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Captopril, placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Oct 4, 2026, 4:00 AM EDT
Not listed Phase 2 Interventional

Pemetrexed Disodium in Treating Patients With Recurrent Malignant Gliomas, Primary CNS Lymphoma, or Brain Metastases

NCT00276783
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Metastatic Cancer
Interventions
pemetrexed
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2022
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced Oct 4, 2026, 4:00 AM EDT
Completed Not applicable Interventional Results available

Impact of Ticagrelor Re-load on Pharmacodynamic Profiles

NCT01731041
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Ticagrelor 180mg, Ticagrelor 90mg
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Oct 4, 2026, 4:00 AM EDT
Withdrawn Phase 3 Interventional

Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C

NCT01447394
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Pegylated Interferon Lambda, Pegylated Interferon Alfa-2a, Ribavirin
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
San Diego, California • Rochester, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 4, 2026, 4:00 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Comparison of a Demand Oxygen Delivery

NCT06609694
View directory record Official record
Conditions
Obstructive Apnea
Interventions
Portable oxygen concentrator Inogen G5 model
Device
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 4, 2026, 4:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of the PelvicSim Simulator for Training in Intrauterine Device Insertions

NCT02220205
View directory record Official record
Conditions
Contraceptive Devices, Intrauterine, Education, Medical
Interventions
PelvicSim, Manufacturer model
Other · Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 24, 2017 · Synced Oct 4, 2026, 4:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

THRIVE Use in Pediatric Populations- Multi Site

NCT04322994
View directory record Official record
Conditions
Oxygen Deficiency, Desaturation of Blood, Hypoventilation, Anesthesia; Adverse Effect
Interventions
Transnasal Humidified Rapid-Insufflation Ventilatory Echange
Device
Lead sponsor
Stanford University
Other
Eligibility
Up to 18 Years
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
5
States / cities
Palo Alto, California • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Oct 4, 2026, 4:00 AM EDT
Terminated Not applicable Interventional Results available

Complex Ventral Hernia Repair Using Biologic or Synthetic Mesh

NCT02041494
View directory record Official record
Conditions
Hernia, Ventral
Interventions
Ventralight, Strattice
Device
Lead sponsor
Hobart Harris
Other
Eligibility
21 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 4, 2026, 4:00 AM EDT
Completed Phase 3 Interventional Results available

Reducing Involuntary Movements in Participants With Tardive Dyskinesia

NCT02198794
View directory record Official record
Conditions
Tardive Dyskinesia
Interventions
SD-809, Placebo
Drug
Lead sponsor
Auspex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
44
States / cities
Tuscaloosa, Alabama • Anaheim, California • Glendale, California + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2022 · Synced Oct 4, 2026, 4:00 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Table-Top Water Pitcher to Reduce Arsenic Exposure Among Well Users in New Hampshire

NCT07103356
View directory record Official record
Conditions
Arsenic Poisoning, Environmental Exposure, Water-Related Diseases
Interventions
Water Pitcher Filtration System
Behavioral
Lead sponsor
Trustees of Dartmouth College
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 4, 2026, 4:00 AM EDT
Completed Phase 3 Interventional

SWOG-9304 Chemotherapy Plus Radiation Therapy in Treating Patients With Rectal Cancer That Has Been Surgically Removed

NCT00002551
View directory record Official record
Conditions
Colorectal Cancer
Interventions
fluorouracil, leucovorin calcium, levamisole hydrochloride, radiation therapy
Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
1,917 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2008
U.S. locations
35
States / cities
Scottsdale, Arizona • Denver, Colorado • Tampa, Florida + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2013 · Synced Oct 4, 2026, 4:00 AM EDT
Terminated Not applicable Interventional Results available

DuraGen Plus® Adhesion Barrier for Use in Spinal Surgery

NCT00387829
View directory record Official record
Conditions
Spinal Injuries, Adhesions
Interventions
DuraGen Plus Adhesion Barrier Matrix
Device
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
36
States / cities
Mobile, Alabama • Beverly Hills, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2017 · Synced Oct 4, 2026, 4:00 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation

NCT00141037
View directory record Official record
Conditions
Kidney Diseases, Kidney Transplantation, Kidney Transplant, Renal Transplantation, Renal Transplant
Interventions
Daclizumab, Mycophenolate mofetil (MMF), Prednisone, Tacrolimus, Ganciclovir, Valganciclovir, Trimethoprim and sulfamethoxazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 21 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Oct 4, 2026, 4:00 AM EDT
Withdrawn Not applicable Interventional

Strength for Health

NCT01882972
View directory record Official record
Conditions
Colon Cancer
Interventions
Exercise, Meditation
Behavioral
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 4, 2026, 4:00 AM EDT
Active, not recruiting Not applicable Interventional

Evaluation of the Safety and Effectiveness of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus

NCT06498960
View directory record Official record
Conditions
Normal Pressure Hydrocephalus
Interventions
CereVasc eShunt System, VP Shunt
Device
Lead sponsor
CereVasc Inc
Industry
Eligibility
60 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
29
States / cities
Los Angeles, California • New Haven, Connecticut • Jacksonville, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 4, 2026, 4:00 AM EDT
Recruiting Early Phase 1 Interventional

Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers

NCT05553782
View directory record Official record
Conditions
Salivary Gland Cancer, Adenoid Cystic Carcinoma of the Salivary Gland, Squamous Cell Carcinoma of Head and Neck, Head and Neck Cancer
Interventions
Implantable Microdevice (IMD)
Combination Product
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 4, 2026, 4:00 AM EDT
Active, not recruiting Phase 2 Interventional

The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer

NCT04699123
View directory record Official record
Conditions
Advanced Non-small Cell Lung Cancer
Interventions
NC318 800 mg, NC318 400 mg, Pembrolizumab
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 4, 2026, 4:00 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

IV Acetaminophen for Postoperative Pain Analgesia After Laparoscopic Hysterectomy

NCT02400580
View directory record Official record
Conditions
Pain
Interventions
IV acetaminophen, placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
183 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Oct 4, 2026, 4:00 AM EDT
Completed Not applicable Interventional Results available

Home Semen Testing in Men Beginning Attempts to Conceive

NCT05503862
View directory record Official record
Conditions
Male Infertility
Interventions
YoSperm
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 4, 2026, 4:00 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma

NCT04850846
View directory record Official record
Conditions
Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
Interventions
Metformin XR, Placebo
Drug · Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Boston, Massachusetts • Brighton, Massachusetts • Methuen, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 4, 2026, 4:00 AM EDT